With the power of BioMap’s foundational life science models, researchers can innovate in various phases of the drug discovery and development process. Credit: BioMap/Business Wire.

BioMap has entered a strategic alliance with Sanofi to co-develop AI modules and expedite drug discovery for biotherapeutics.

Drug discovery will be carried out leveraging BioMap’s AI platform that integrates super-scale computing and large language models with advanced biotechnology.

Related Company Profiles

View all

The platform helps to discover new targets and design biologics through an understanding of proteins.

Sanofi will make an upfront cash payment of $10m (€9.43m) and further near-term payments to BioMap for reaching module development milestones.

Based on the achievement of pre-clinical development, clinical development, and regulatory and commercial milestones, BioMap is entitled to receive more than $1bn.

See Also:

BioMap chief technology officer Le Song stated: “As the largest foundational model-based approach within life sciences, we are thrilled to collaborate with Sanofi and leverage the potential of BioMap’s cutting-edge AI engine to help solve complex problems associated with new protein therapies to drive drug discovery.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

BioMap’s foundational models and AI expertise, together with Sanofi’s data, computational protein engineering innovations and biologics development experience, will be leveraged to create advanced AI models and protein large language models.

Sanofi Research Platforms global head Matt Truppo stated: “By combining Sanofi’s proprietary data sets, digital infrastructure, AI and data science capabilities, and drug development expertise with BioMap’s protein large language models, high-performance computing and deep understanding of AI, we can optimise the process of discovery and development of breakthrough biotherapeutics.

“Our collaboration with BioMap further underscores Sanofi’s commitment to becoming the first pharma company powered by artificial intelligence at scale.”